Comments
Alembic Pharmaceuticals today said no observations were issued by US health regulator USFDA after inspection of its Baroda facility.
The bio-equivalence facility was inspected by US Food & Drug Administration (USFDA) from March 6-10; March 13-17 and April 10-12, Alembic said in a filing to BSE.
“There were no 483s issued by USFDA at the end of the inspection,” it added.
USFDA issues Form 483 observations to a firm’s management at the conclusion of an inspection to notify it of objectionable conditions at the facility.
It is issued when investigator(s) has observed any conditions that in their judgement may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.
The Alembic stock was trading at Rs 626.80, up 0.35 per cent, in afternoon trade on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.